NEW YORK--(BUSINESS WIRE)--Levels, the first biowearable system to give real-time biofeedback on nutrition and lifestyle, today announced that Dr. Gerald Shulman, MD-PhD, has joined the company as an Advisor. In this role, Dr. Shulman will advise on our strategy and collaborate with Levels on research to understand better the physiologic drivers of insulin resistance and other metabolic dysfunction.
Dr. Shulman is the George R. Cowgill Professor of Medicine and Professor of Cellular and Molecular Physiology at Yale. He is also Co-Director of the Yale Diabetes Research Center and was an Investigator of the Howard Hughes Medical Institute for 21 years.
“Dr. Shulman’s work has been groundbreaking for our understanding of the molecular basis of insulin resistance and the mechanisms driving the development of metabolic disease, as well as opportunities for disease reversal,” says Josh Clemente, Founder of Levels. “His research has shown that young, lean, non-diabetic individuals can display significant insulin resistance and dysfunctional metabolic processes, long before fasting glucose levels markedly change, and he’s highlighted factors that could explain why this occurs. We are thrilled to work with Dr. Shulman to understand the critical steps in the development of metabolic dysfunction so that we can empower people to make choices that intervene in these processes early and directly.”
Dr. Shulman is known for pioneering magnetic resonance spectroscopy combined with mass spectrometry to non-invasively examine intracellular glucose and fat metabolism in humans and transgenic rodent models. These advances have led to several paradigm shifts in our understanding of Type 2 diabetes (T2D), as well as the development of new drugs for the treatment of T2D, nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis. He has been the recipient of numerous awards and honors for his work.
For more information, visit levelshealth.com.
Levels is the first biowearable system to provide real-time feedback on how food impacts your health in real-time. By leveraging continuous glucose monitoring technology, the Levels program helps users close the loop between their health and their daily lifestyle choices around food, exercise, sleep, and stress management. Our customers are losing weight, discovering their optimal diet, and reducing long-term risk factors.
In November 2020, Levels raised a $12M seed round led by Andreessen Horowitz with participation from Marc Randolph (co-founder, Netflix), Esther Dyson, Dick Costolo (former CEO, Twitter), Michael Arrington (Founder, TechCrunch), Matt Dellavedova (NBA, Cleveland Cavaliers), and others. Levels is currently running a closed beta program focused on product development and has a waitlist of over 115,000 people.
Team and Mission
Casey Means MD (Stanford MD), Josh Clemente (SpaceX, Hyperloop), Sam Corcos (CarDash, YC), David Flinner (Google), and Andrew Conner (Google) founded Levels to solve the metabolic health crisis. Almost 10% of the United States is diabetic—and that rate is growing globally at an increasing rate. In addition, 84 million Americans are prediabetic, and 70% could have Type 2 diabetes within 10 years. Levels is starting with the tech-forward, health-seeking market to build brand credibility and thought leadership before moving into mainstream health and wellness in 2022 and beyond.